According to Zacks, “Sartorius AG is a pharmaceutical and laboratory equipment supplier. The company manufactures equipment for biomolecular and microbial separations, cell culture, concentration, fermentation and purification. Sartorius AG is headquartered in Goettingen, Germany. “
Separately, DZ Bank reiterated a sell rating on shares of Sartorius in a research note on Friday, July 19th.
Sartorius (OTCMKTS:SARTF) last issued its quarterly earnings results on Friday, July 19th. The company reported $0.87 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.80 by $0.07. Sartorius had a return on equity of 20.23% and a net margin of 11.10%. The company had revenue of $515.83 million for the quarter, compared to analyst estimates of $482.51 million. As a group, research analysts forecast that Sartorius will post 3.53 EPS for the current fiscal year.
There is no company description available for Sartorius AG.
Recommended Story: What Factors Can Affect Return on Equity?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.